M2 Presswire - SMITHKLINE BEECHAM: Study shows early treatment with Pa Parkinson’s drug Requip reduces risk of dyskinesias.
M2 PRESSWIRE-30 July 1999-SMITHKLINE BEECHAM: New study shows early treatment with Parkinson’s drug Requip significantly reduces the risk of dyskinesias and is effective long-term (C)1994-99 M2 COMMUNICATIONS LTD RDATE:290799 Vancouver, Canada — Reports of Parkinson’s disease affecting public figures such as Janet Reno, Michael J.
Related Results
Requip for RLSRequip reduces risk of dyskinesiasRequip now has generic competitorsGSK’s Requip significantly improves restless legs syndromeRequip shows use for restless legs syndrome.
Fox and Muhammad Ali have increased awareness of the prevalence of the disease and its impact on patients’ lives. Now a landmark study released this week at the 13th International Congress on Parkinson’s Disease in Vancouver shows that SmithKline …
Read the rest of this article with a Free Trial at HighBeam Research.
